摘要
目的探讨CXC趋化因子受体4(CXCR4)在甲状腺癌组织中的表达水平及与CD163肿瘤相关巨噬细胞(TAMs)的相关性。方法选取行手术治疗的甲状腺癌患者73例,采用免疫组化分析甲状腺癌组织CXCR4的表达水平和CD163 TAMs的密度,探讨CXCR4的表达水平与临床特征及预后的关系,分析CXCR4的表达水平和CD163 TAMs的相关性。结果 73例患者中CXCR4的平均表达CES评分为4.27±2.10,CD163 TAMs平均密度为(5.92±4.33)%,肿瘤分期Ⅲ～Ⅴ期、未分化癌和存在淋巴结转移患者的CXCR4表达和CD163巨噬细胞密度显著增高,差异有统计学意义(P<0.05)。CXCR4表达CES评分和CD163巨噬细胞密度呈正相关(r=0.58,P<0.001),CXCR4高表达患者的总体生存率显著低于CXCR4低表达的患者(HR=3.419,95%CI:1.352～8.646,P=0.009 4)。结论甲状腺癌中CXCR4的表达水平及CD163 TAMs均密度与肿瘤分期、肿瘤类型和淋巴结转移具有密切的关系,CXCR4的表达水平及CD163 TAMs均密度呈正相关,且高CXCR4表达的甲状腺癌患者预后不良。
引文
[1] Lo TE,Jimeno CA,Paz-Pacheco E.Anaplastic thyroid cancer:experience of the Philippine General Hospital[J].Endocrinol Metab (Seoul),2015,30(2):195-200.
[2] Brignardello E,Gallo M,Baldi I,et al.Anaplastic thyroid carcinoma:clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years[J].Eur J Endocrinol,2007,156(4):425-430.
[3] Nagaiah G,Hossain A,Mooney CJ,et al.Anaplastic thyroid cancer:a review of epidemiology,pathogenesis,and treatment[J].J Oncol 2011,2011:542358.
[4] 胡金华,张耀晴,艾瑞华,等.分化型甲状腺癌患者血清TNF-α、IL-6和VEGF表达与侵袭转移的相关性分析[J].现代肿瘤医学,2015,23(6):771-774.
[5] Cho SW,Kim YA,Sun HJ,et al.Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling[J].J Clin Endocrinol Metab,2014,99(9):E1641-E1649.
[6] Campbell MJ,Tonlaar NY,Garwood ER,et al.Proliferating macrophages associated with high grade,hormone receptor negative breast cancer and poor clinical outcome[J].Breast Cancer Res Treat,2011,128(3):703-711.
[7] Jung KY,Cho SW,Kim YA,et al.Cancers with higher density of tumor-associated macrophages were associated with poor survival rates[J].J Pathol Transl Med,2015,49(4):318-324.
[8] Kim S,Cho SW,Min HS,et al.The expression of tumor-associated macrophages in papillary thyroid carcinoma[J].Endocrinol Metab (Seoul),2013,28(3):192-198.
[9] Sato S,Hanibuchi M,Kuramoto T,et al.Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment[J].Clin Exp Metastasis,2013,30(3):333-344.
[10] 王明华,黄铁柱,惠震,等.趋化因子受体CXCR4在甲状腺癌中的表达[J].肿瘤防治研究,2008,35(2):107-109.
[11] 吴金健,陈永香,文芳,等.靶向阻断CXCR4对卵巢上皮性癌上皮间质转化影响的研究[J].实用妇产科杂志,2017,33(11):843-847.
[12] 唐威,李劲东.甲状腺癌组织中趋化因子4受体和趋化因子7受体的表达情况及临床病理意义[J].标记免疫分析与临床,2015,22(5):450-452,473.
[13] Rogers TL,Holen I.Tumour macrophages as potential targets of bisphosphonates[J].J Transl Med,2011,9(1):177.
[14] Zhang QW,Liu L,Gong CY,et al.Prognostic significance of tumor-associated macrophages in solid tumor:a meta-analysis of the literature[J].PLoS One,2012,7(12):e50946.
[15] Qing W,Fang WY,Ye L,et al.Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma[J].Thyroid,2012,22(9):905-910.
[16] Ryder M,Ghossein RA,Ricarte-Filho JC,et al.Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer[J].Endocr Relat Cancer,2008,15(4):1069-1074.
[17] Ambarus CA,Krausz S,van Eijk M,et al.Systematic validation of specific phenotypic markers for in vitro polarized human macrophages[J].J Immunol Methods,2012,375(1/2):196-206.
[18] Passaro C,Borriello F,Vastolo V,et al.The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma[J].Oncotarget,2016,7(2):1500-1515.
[19] Vishvakarma NK,Singh SM.Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host:implication in antitumor activation of tumor-associated macrophages[J].Immunol Lett,2010,134(1):83-92.
[20] Boimel PJ,Smirnova T,Zhou ZN,et al.Contribution of CXCL12 secretion to invasion of breast cancer cells[J].Breast Cancer Res,2012,14(1):R23.
[21] Walter DH,Haendeler J,Reinhold J,et al.Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease[J].Circ Res,2005,97(11):1142-1151.
